DETAX
Develops biocompatible silicones and high-performance 3D resins for dental and medical applications, enabling MDR-certified additive manufacturing.
- CEO / Founder
- Dr. Sönke Rössing
- Team Size
- 51-200
- Stage
- Active
- Total Funding
- Undisclosed
- Latest Round
- Private Equity
- Key Investors
- ECM Equity Capital Management; PINOVA Capital; Gilde Healthcare Private Equity
Technology & Products
Key Products
FREEPRINT crown; FREEPRINT denture; HIGHCLASS 3D resins
Technological Advantage
Proprietary polymer chemistry for silicones and light-curing resins with MDR certification and validated workflows for multiple 3D printing systems.
Differentiation
Value Proposition
Provides MDR-certified, high-performance polymer resins for dental and otoplastic 3D printing, ensuring biocompatibility and precision for medical devices.
How They Differentiate
Combines 70+ years of polymer chemistry expertise with pioneer status in dental 3D printing resins, offering a fully MDR-certified portfolio validated for multiple hardware systems.
Market & Competition
Target Customers
Dental practices, dental laboratories, audiologists, and audio laboratories.
Industry Verticals
Dental; Medical; Otoplastic
Competitors
Dreve; NextDent (3D Systems); Keystone Industries
Growth & Milestones
Growth Metrics
Employs ~110 people; revenue ~$5.5M
Major Milestones
Founded in 1954; Management buy-out by Investor Consortium (2018-2019); FDA clearance for FREEPRINT (2020, 2022); Dr. Sönke Rössing becomes CEO, Thorsten Preiss becomes CFO (2024)
Notable Customers
Hörluchs; Neuroth; Zirkonzahn